Search

Your search keyword '"Cancer Research Institute"' showing total 27,241 results

Search Constraints

Start Over You searched for: Author "Cancer Research Institute" Remove constraint Author: "Cancer Research Institute"
27,241 results on '"Cancer Research Institute"'

Search Results

101. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

102. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

103. Confounding factors in the assessment of oral mucositis in head and neck cancer

104. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

105. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors

106. Host IL11 Signaling Suppresses CD4+ T cell–Mediated Antitumor Responses to Colon Cancer in Mice

107. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

110. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

111. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

112. Fgf8 dynamics and critical slowing down may account for the temperature independence of somitogenesis

115. Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

116. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

117. The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification

118. Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro—In Vivo Correlation

119. SAGA-Dependent Histone H2Bub1 Deubiquitination Is Essential for Cellular Ubiquitin Balance during Embryonic Development

120. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

121. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

125. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

126. Current and potential diagnostic modalities in the detection and management of breast cancer

127. Actin Dynamics at the T Cell Synapse as Revealed by Immune-Related Actinopathies

128. A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors

129. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

131. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

132. Histone H2Bub1 deubiquitylation is essential for mouse development, but does not regulate global RNA polymerase II transcription

133. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

134. Cancer drug resistance induced by EMT: novel therapeutic strategies

135. Brain metastasis models: What should we aim to achieve better treatments? [preprint]

149. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

150. Cancer drug resistance induced by EMT: novel therapeutic strategies

Catalog

Books, media, physical & digital resources